Clinical Trials Browser

OTHER × Prostatic Neoplasms × Folic Acid × Clear all

NCT00216099 2016-07-29

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

Phase 2 Completed

49 enrolled 15 charts

Prostatic Neoplasms